

Visit **alere-i.com** today
or contact alere-i@alere.com

Ordering Information

NAT-024	Alere™ i Instrument	EQ001001	Alere™ i Barcode Scanner
425-024	Alere™ i Influenza A & B 24 Test Kit, CPT: 87502	55115	Alere™ Universal Printer
425-080	Alere™ i Influenza A & B Control Swab Kit		

Transforming near-patient testing

Unique isothermal amplification technology giving you molecular results, faster than ever before



Improving patient outcomes

Giving you the confidence to make appropriate clinical decisions sooner



Optimizing operational efficiency

- Facilitating effective patient management
- Enables prompt initiation of infection control measures
- Connected results direct to your network



Enabling effective Antimicrobial Stewardship

Molecular sensitivity in an actionable timeframe allows the prudent use of antibiotics and antivirals




A positive impact on your facility

Reliable near-patient testing reduces overall healthcare costs³



Confidence at the point of care


Intuitive and reliable, allowing you to respond quickly and accurately in any setting



The Test Target Treat™ antimicrobial stewardship initiative from Alere empowers you to make targeted treatment decisions sooner with rapid diagnostics; reducing the inappropriate use of antibiotics and antivirals, and the spread of resistance.



Find out more at **TestTargetTreat.com**



**TEST
TARGET
TREAT™**

References

1. Alere™ i Influenza A & B Package Insert
2. Bell, J. *et al.* (2013) Clinical Evaluation of the Alere™ i Influenza A & B Assay, a Point-of-Care Rapid Nucleic Acid Amplification Test for Detection of Influenza. Children's Mercy Hospitals and Clinics and University of Missouri Kansas City School of Medicine, Kansas City, MO. Veritas, P.A., Belton, TX. Nationwide Children's Hospital, Columbus, OH. New York Methodist Hospital, Brooklyn, NY. Ann & Robert Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine, Chicago, IL. Albany Medical College, Albany, NY. Wake Forest University Baptist Medical Center, Winston-Salem, NC.
3. Bonner, A.B. *et al.* (2003) Impact of the Rapid Diagnosis of Influenza on Physician Decision-Making and Patient Management in the Pediatric Emergency Department: Results of a Randomized, Prospective, Controlled Trial. *Pediatrics* Vol. 112 No. 2.




Call **1.877.441.7440** or visit **alere.com** today



Alere™ i Influenza A & B
Molecular results in less than 15 minutes

Alere™ i Molecular. In minutes.™

Faster Results



Alere™ i is **significantly faster** than **other** molecular methods and more **accurate** than conventional rapid testing giving you the **confidence** to make **effective patient management decisions sooner**.

Unique Technology

Alere™ i utilizes our **unique isothermal nucleic acid amplification technology** which does not require temperature cycling or a sample purification step.

Outstanding Performance

Alere™ i Influenza A & B vs. Culture¹

	Sensitivity	Specificity
Influenza A	97.9% (95% CI: 92.6%, 99.4%)	86.2% (95% CI: 82.8%, 89.0%)
Influenza B	92.5% (95% CI: 84.6%, 96.5%)	96.5% (95% CI: 94.5%, 97.8%)

Alere™ i Influenza A & B vs. Culture¹

Discrepant results resolved by RT-PCR*

	Sensitivity	Specificity
Influenza A	99.3% (95% CI: 96.3%, 99.9%)	98.1% (95% CI: 96.3%, 99.0%)
Influenza B	97.8% (95% CI: 92.3%, 99.4%)	99.6% (95% CI: 98.5%, 99.9%)

* Flu A nucleic acid was detected in 58/66 False Positive specimens using an FDA-cleared molecular test
Flu A nucleic acid was not detected in 1/2 False Negative specimens using an FDA-cleared molecular test
Flu B nucleic acid was detected in 15/17 False Positive specimens using an FDA-cleared molecular test
Flu B nucleic acid was not detected in 4/6 False Negative specimens using an FDA-cleared molecular test

“Alere™ i demonstrates **impressive sensitivity** for the detection of both **influenza A and B** in clinical respiratory specimens obtained from children and adults.”²

Intuitive Design

- **Sample type** nasal swab
- **Visual touchscreen** no need for separate instructions
- **Easy to use** requires only minimal training
- **Small footprint** can be used in any healthcare setting
- **Streamlined workflow** connectivity can be provided to your network



“A **simple** and **easy to use** molecular diagnostic test.”²

